Similar articles

• Malondialdehyde and C-reactive protein as prognostic markers of hepatocellular carcinoma.

  Elbaz S, Mousa N, Besheer T, Sheta T, Taha K, Awad M, Effat N, Elgamal A, Abdel-Razik A. Elbaz S, et al. Br J Biomed Sci. 2020 Apr;77(2):94-96. doi: 10.1080/09674845.2020.1715073. Epub 2020 Feb 25. Br J Biomed Sci. 2020. PMID: 31971480 No abstract available.
• Diagnosis: Novel prognostic biomarkers in hepatocellular carcinoma.

  Pang RW, Poon RT. Pang RW, et al. Nat Rev Gastroenterol Hepatol. 2012 Dec;9(12):691-2. doi: 10.1038/nrgastro.2012.208. Epub 2012 Nov 13. Nat Rev Gastroenterol Hepatol. 2012. PMID: 23147657 No abstract available.
• Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.

  Sieghart W, Pinter M, Hucke F, Graziadei I, Schöniger-Hekele M, Müller C, Vogel W, Trauner M, Peck-Radosavljevic M. Sieghart W, et al. Hepatology. 2013 Jun;57(6):2224-34. doi: 10.1002/hep.26057. Epub 2013 Jan 18. Hepatology. 2013. PMID: 22961713
• Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma.

  Zou ZQ, Ding YP, Long B, Yuh JG, Xu AL, Lang ZW, Zou SY, Liu YD, Ding K, Li YY. Zou ZQ, et al. Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1285-90. Hepatogastroenterology. 2010. PMID: 21410073 Review.
• [Why no consensus prognostic classification for hepatocellular carcinoma?].

  Barbare JC, Bellenguez A, Diouf M. Barbare JC, et al. Rev Prat. 2013 Feb;63(2):218-9. Rev Prat. 2013. PMID: 23513789 Review. French. No abstract available.